House AER bill
This article was originally published in The Tan Sheet
Rep. Chris Cannon (R-Utah) introduces a House version of legislation mandating adverse event reporting for dietary supplements and OTC drugs Sept. 25. The bill goes to the House Committee on Energy & Commerce, where a hearing is expected shortly after the House reconvenes in November. The "Dietary Supplement & Nonprescription Drug Consumer Protection Act" (HR 6168) requires manufacturers, packers or distributors of OTC drugs or dietary supplements "whose name appears on the label" to report any serious adverse events to FDA, the legislation states. The provisions of the bill would take effect one year after enactment. Sen. Orrin Hatch (R-Utah) believes the introduction of the House supplement AER bill "will boost [the legislation's] prospects for enactment this Congress," according to a staffer. It is likely the Senate will vote on the related legislation (S 3546) in early October, according to several supplement industry trade groups (1"The Tan Sheet," Sept. 18, 2006, p. 6)...
You may also be interested in...
Adverse Event Bill Down To The Wire As Congress Wraps Up
Congress was poised late last week to pass a bill requiring mandatory adverse event reporting for dietary supplements and nonprescription drugs
Senate Vote On Adverse Event Reporting Bill Expected By October
The Senate likely will vote on the "Dietary Supplement & Nonprescription Drug Consumer Protection Act" (S 3546) before they adjourn in early October, according to several supplement industry trade groups
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.